Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia

Abstract

Patients with thrombophilia remain concerned about venous thromboembolism (VTE) risk with COVID-19 vaccinations. The aim of this study was to examine VTE outcomes in patients with inherited or acquired thrombophilia who were vaccinated for COVID-19. Vaccinated patients ≥18 years between November 1, 2020 and November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE occurring 90 days before and after the date of the first vaccine dose. Thrombophilia patients

Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination

“…A large observational study from the Mayo Clinic, Rochester, Minnesota, USA, identified 6067 patients with confirmed thrombophilia among almost 800,000 vaccinated patients against COVID-19. Subgroup analysis did not find any statistically significant difference in the occurrence of venous thromboembolism between patients with and without thrombophilia vaccinated against COVID-19 [57].…”

Risk of pulmonary embolism and deep vein thrombosis following COVID‐19: a nationwide cohort study

“…A recent US study showed no difference in venous thromboembolism rate when compared 90 days before and after COVID‐19 vaccination. 25 Another recent study from the United States demonstrated that one case of mRNA vaccination was considered vaccine‐induced immune thrombotic thrombocytopenia within 4–28 days after the vaccination, from a total of 74 thrombosis cases. 26 In contrast, a recent self‐controlled cases series study reported that COVID‐19 vaccination increased the risk of thrombocytopenic, hemorrhagic, and thromboembolic events.…”

SARS‐CoV‐2 vaccination appears to be safe in antiphospholipid antibody syndrome: Comment on evaluation of patients with antiphospholipid syndrome subsequently COVID‐19 vaccinations

“…Most of these studies did not report any thrombotic events or any increase in the titers or prevalence of APLs in APS patients following COVID-19 vaccination. 1,[4][5][6][7][8] A large cohort study from the Mayo Clinic, Rochester, MN, USA, identified no significant differences in the risk of venous thrombosis in the 3 months following COVID-19 vaccination when compared with the 3 months preceding vaccination. 7 Four studies assessed the prevalence of APLs in healthy individuals following COVID-19 vaccination.…”

“…1,[4][5][6][7][8] A large cohort study from the Mayo Clinic, Rochester, MN, USA, identified no significant differences in the risk of venous thrombosis in the 3 months following COVID-19 vaccination when compared with the 3 months preceding vaccination. 7 Four studies assessed the prevalence of APLs in healthy individuals following COVID-19 vaccination. Overall, very few people developed APLs after vaccination and no increased thrombotic risk was noted in such individuals.…”

“…The identified studies are summarized in Table 1. 1,[4][5][6][7][8][9][10][11][12] Six studies assessed the safety of COVID-19 vaccination in more than 1300 patients with APS. Most of these studies did not report any thrombotic events or any increase in the titers or prevalence of APLs in APS patients following COVID-19 vaccination.…”